<DOC>
	<DOCNO>NCT02855684</DOCNO>
	<brief_summary>Primary Objective : To compare efficacy insulin glargine ( U300 ) Lantus term change glycated hemoglobin A1c ( HbA1c ) baseline endpoint ( schedule Month 6 , Week 26 ) patient type 2 diabetes mellitus . Secondary Objectives : - To compare insulin glargine ( U300 ) Lantus term occurrence hypoglycemia nocturnal hypoglycemia . - To compare insulin glargine ( U300 ) Lantus term reach target HbA1c value ( reach target without hypoglycemia ) . - To compare insulin glargine ( U300 ) Lantus term control plasma glucose ( reach target without hypoglycemia ) . - To compare frequency occurrence diurnal distribution hypoglycemia category hypoglycemia ( document symptomatic , asymptomatic , nocturnal , severe , probable relative ) . - To assess safety tolerability insulin glargine ( U300 ) . - To assess development anti-insulin glargine antibody ( AIA ) .</brief_summary>
	<brief_title>Comparison Efficacy Safety New Formulation Insulin Glargine With Lantus Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy</brief_title>
	<detailed_description>The total maximum study duration per patient 29 week consist 2-week screening period , 26-week treatment period , 2-day post-treatment safety follow-up period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Inclusion criterion : Adult patient type 2 diabetes mellitus inadequately control noninsulin antihyperglycemic drug ( ) . Signed write informed consent . Exclusion criterion : Age &lt; legal age adulthood . HbA1c &lt; 7.0 % ( &lt; 53 mmol/mol ) &gt; 11 % ( &gt; 97 mmol/mol ) ( screen ) . History type 2 diabetes mellitus less 1 year screening . Less 6 month screen noninsulin antihyperglycemic treatment . Change dose noninsulin antihyperglycemic treatment last 3 month screening . Initiation new glucoselowering medication and/or weight loss drug last 3 month screen visit and/or initiation glucagon like peptide1 ( GLP1 ) receptor agonist last 6 month screen visit . Patients receive noninsulin antihyperglycemic drug approve combination insulin accord local labeling ( Note : noninsulin antihyperglycemic drug approve combination insulin discontinue randomization ) . Current previous insulin use except maximum 10 consecutive day ( eg , acute illness , surgery ) last one year prior screen . Severe hypoglycemia result coma/seizures , and/or hospitalization diabetic ketoacidosis last 6 month screen visit . Unstable proliferative diabetic retinopathy rapidly progressive diabetic retinopathy macular edema likely require treatment ( eg , laser , surgical treatment injectable drug ) study period . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>